Reverse signaling via pd-l1 supports malignant cell growth and survival in classical hodgkin lymphoma

ABSTRACT Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating

that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling

through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed–Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an

agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. We show that HL patients have significantly higher serum levels of soluble

PD-1 than healthy controls, and find that both membrane-bound and soluble forms of PD-1 are able to induce PD-L1 reverse signaling in HL cell lines. PD-L1 signaling, which is associated with

activation of the MAPK pathway and increased mitochondrial oxygen consumption, is reversed by PD-1 blockade. In summary, our data identify inhibition of reverse signaling through PD-L1 as

an additional mechanism that accounts for clinical responses to PD-1 blockade in cHL. SIMILAR CONTENT BEING VIEWED BY OTHERS PROGRAMMED DEATH LIGAND 1 SIGNALS IN CANCER CELLS Article 14

January 2022 DUAL BTK/SYK INHIBITION WITH CG-806 (LUXEPTINIB) DISRUPTS B-CELL RECEPTOR AND BCL-2 SIGNALING NETWORKS IN MANTLE CELL LYMPHOMA Article Open access 16 March 2022 MTOR INHIBITION

AMPLIFIES THE ANTI-LYMPHOMA EFFECT OF PI3KΒ/Δ BLOCKAGE IN DIFFUSE LARGE B-CELL LYMPHOMA Article Open access 09 November 2022 INTRODUCTION The advent of immunotherapy targeting immune

checkpoint molecules has been associated with significant improvements in the treatment of several neoplasms, including hematological malignancies1. Programmed death-1 (PD-1) and its two

cognate ligands, PD-L1 and PD-L2, are immune modulatory molecules that are expressed on both hematopoietic and non-hematopoietic cells and are involved in maintaining immune homeostasis.

While the interaction of PD-1 with its ligands is necessary for immune tolerance, it can provide a mechanism for cancer cells to escape from immune surveillance. In fact, increased

expression of PD-1 ligands by cancer cells, arising from either genetic alteration or microenvironmental triggers, and their binding to PD-1 receptors on the surface of T cells has been

shown to attenuate T-cell receptor (TCR)-mediated signaling and result in an exhausted T-cell phenotype that can prevent lysis of tumor cells2,3. Classical Hodgkin lymphoma (cHL) is a B-cell

malignancy that is characterized by the presence of a small number (1–5%) of Hodgkin Reed–Sternberg (HRS) cells surrounded by an extensive infiltration of various immune cell types that

comprise more than 90% of the cells within the tumor lesion. Analysis of the immune cells has identified CD4 + T cells as the predominant cell population within tumor microenvironment in

cHL. The CD4+ T-cell population contains PD-1 + Th1-polarized, rather than Th2-polarized, effector T cells and also PD-1-negative regulatory T cells4,5,6,7, implying an immunosuppressive

microenvironment. PD-1 + CD4 + T cells, together with tumor-associated macrophages (TAMs) are located in close proximity to HRS cells, comprising a unique niche in cHL8. Overexpression of

PD-L1 and PD-L2, driven by genetic alterations and deregulated signaling pathways, has been identified in HRS cells and mediates immune evasion by HRS cells. Amplification or copy number

gain of chromosome 9p24.1 has been identified in almost all cHL patients and has shown to be associated with increased transcript levels of PD-1 ligands in both cHL cell lines and primary

HRS cells9. Elevated levels of PD-L1 are also observed in cHL with normal or low 9p24.1 amplification, an effect that is regulated by AP-1 activation and EBV infection10. The increased

expression of PD-1 ligands is predicted to induce immune suppression upon engagement of PD-1 receptors on effector T-cells, thereby creating a strong rationale for blocking PD-1 signaling to

clinically benefit patients with cHL. Clinical use of anti-PD-1 antibodies has resulted in response rates of 65–87% in relapsed or refractory HL patients11,12,13, implying that the blockade

of PD-1/PD-L1 or -L2 signaling could trigger a T-cell-mediated immune response against tumor neoantigens. However, lack or reduced HRS cell surface expression of β2-microglobulin, MHC class

I, and MHC class II complex, which are seen in 80%, 78%, and 67% of the cHL patients, respectively14, restricts antigen presentation and effector T-cell function suggesting that other

mechanisms may be relevant. Recent results have shown that genetically driven PD-L1 expression and MHC class II positivity on HRS cells in cHL, rather than MHC class I expression, are

potential predictors of favorable outcome after PD-1 blockade15. While this suggests a CD4 + T cell-mediated mechanism of response, a subset of patients with MHC class II-negative HRS cells

also responded to PD-1 blockade, suggesting that additional mechanisms may play a role. Owing to the genetically driven PD-L1 amplification in HRS cells and the association of PD-L1

expression with response to PD-1 blockade, we explored the role of PD-L1 reverse signaling in the context of immune checkpoint inhibition in cHL. RESULTS PD-L1 REVERSE SIGNALING INCREASES

SURVIVAL AND PROLIFERATION OF THE HL CELL LINES HL cells express elevated levels of PD-L1 as a result of either chromosome 9p24.1 amplification or EBV infection. While the interaction of

PD-L1 with its receptor PD-1 could suppress T-cell function, the reverse effect of such an interaction on the HL cells has not been elucidated. We used an agonistic mouse monoclonal antibody

targeting PD-L116 (provided by Dr. Dong) to stimulate PD-L1 on the cell surface of HL cell lines to study the reverse signaling through PD-L1. Using flow-cytometry analysis, we first

examined the expression of PD-L1 by all four HL cell lines (HL-428, HL-1236, HL-HDLM2, and HL-KMH2) used in this study. Our data showed PD-L1 surface expression on all cell lines. Mean

fluorescent intensities (MFI) were reported as: HL-428 (Isotype control: 623, PD-L1: 967), HL-1236 (Isotype control: 1522, PD-L1: 8270), HL-HDLM2 (Isotype control: 492, PD-L1: 5432), and

HL-KMH2 (Isotype control: 297, PD-L1: 532) (Supplementary Fig. 1A). To ensure that it is the PD-L1 that transmits the signals and no other ancillary receptor is involved, the four different

HL cell lines were starved overnight and then seeded over the plates coated with 10 μg/ml of either IgG1 isotype (control) or PD-L1 antibody in the starvation culture medium. As a result of

starvation for 2 days, control cells underwent apoptosis and cell death (Fig. 1a), while cells incubated with the PD-L1 antibody showed a considerably reduced level of both apoptosis and

cell death (Fig. 1a), indicating that the incoming signal from PD-L1 significantly promoted the survival of the tumor cells. To further confirm the engagement of PD-L1 by the PD-L1 agonistic

antibody, we treated HL cells (either the parent line or PD-L1 overexpressing cells) with a PD-L1-blocking antibody prior to seeding them on the PD-L1 agonistic antibody-coated plates. Our

data showed a shift toward increased apoptosis in this group of the cells, verifying that reverse signaling via PD-L1 enhances cell survival in HL cells (Supplementary Fig. 1B). We then

examined the effect of the PD-L1 antibody on HL cell proliferation. As shown in Fig. 1B, HL cells treated with the PD-L1 antibody had significantly increased proliferation when compared with

control cells. We next utilized an array-based analysis to identify the proteins that are involved in mediating increased survival of HL cells due to the PD-L1 reverse signaling. Our data

using HL-428 cells identified several apoptotic proteins and phosphoproteins, which were highly downregulated in the presence of PD-L1 antibody, including Bcl-x, procaspase 3, XIAP,

survivin, and phospho-p53 (Fig. 1c). Furthermore, p53 also had a role in the anti-apoptotic effect induced by PD-L1 reverse signaling, as expression of phospho-p53 proteins were profoundly

reduced in this analysis (Fig. 1c). PD-L1 REVERSE SIGNALING IS ASSOCIATED WITH THE MAPK PATHWAY IN HL TUMOR CELLS A previous study has shown that reverse signaling through PD-L1 can occur in

cytotoxic T cells and that engagement of PD-L1 by an agonistic antibody increases phosphorylation of P3816. To determine whether increased survival and proliferation of the HL cells in

response to the PD-L1 antibody is linked to the MAPK signaling molecules, we tested the phosphorylation of both P38- and ERK–MAPK (p-P38 and p-ERK) in the control IgG1 isotype or

anti-PD-L1-treated HL lines. As shown in Fig. 1d, in response to the agonistic anti-PD-L1 antibody, both p-P38 and p-ERK decreased in all HL lines, consistent with previous data showing that

decreased phosphorylation of P38 provides a pro-survival signal16. This implied that signaling through PD-L1 employs the MAPK pathway and that there is an inverse correlation between cell

survival and phospho-MAPK levels. TREATMENT WITH NIVOLUMAB REVERSES THE PD-L1 REVERSE SIGNALING PHENOTYPE INDUCED BY PD-1/PD-L1 INTERACTION We hypothesized that interactions between PD-1

ligands and the PD-1 receptor would provide a similar signal to that seen when the agonistic anti-PD-L1 antibody was used. We first tested the stimulatory effects of membrane-bound PD-1 and

evaluated the effect of the blocking antibody nivolumab in counteracting such effects. We generated doxycycline-inducible PD-1 overexpressing HEK293 cells to be used as the membrane-bound

receptor for PD-L1. Coculture of the HL-428 and HL-1236 cells with PD-1-expressing HEK293 cells resulted in reduced p-ERK protein in HL cells, and treatment with nivolumab reversed this

effect and increased p-ERK to normal levels (Fig. 2a). Given that reduced phosphorylation of ERK and P38 is associated with a pro-survival signal16 (Fig. 1d), these data were consistent with

the flow-cytometry results showing reduced p-ERK levels in response to incubation with the agonistic anti-PD-L1 antibody (Fig. 1d), and confirms the fact that PD-L1 reverse signaling also

occurs as a consequence of PD-L1/PD-1 interaction. Furthermore, treatment with an anti-PD-1 antibody, nivolumab, counteracts this signaling process. HODGKIN LYMPHOMA PATIENTS HAVE ELEVATED

CIRCULATING LEVELS OF SOLUBLE PD-1 Owing to the modest expression of PD-1 seen in cHL patient biopsies, we tested whether soluble PD-1 was increased in patient sera and could provide a

similar agonistic signal. Because, increased levels of soluble immune checkpoint molecules including PD-1 have been shown to be a prognostic factor in several malignancies17,18,19,20, we

first measured the soluble form of PD-1 in the serum of cHL patients and compared the levels to those seen in matched normal controls. As shown in Fig. 2b, soluble PD-1 concentrations were

significantly higher (_p_ < 0.0001) in the patient’s serum than normal subjects, suggesting a potential biological significance of this molecule in the peripheral circulation. In a

separate set of the experiments, we utilized a recombinant PD-1 protein (Fc Chimera), as the soluble receptor and addressed the function of soluble PD-1 in inducing PD-L1 reverse signaling.

Given that proliferating malignant cells have increased energy demand and interfering with this process could prevent malignant cell growth and survival, we treated HL cells with soluble

PD-1 and examined the oxygen consumption rate (OCR) of HL cell lines, as a measure of mitochondrial respiration and metabolic status of the malignant cells. Except for HL-428-PD-L1, basal

OCR level did not differ between different treatment groups in HL-1236 and HL-HDLM2. However, spare respiratory capacity of all three HL lines was increased in response to soluble PD-1 and

addition of the anti-PD-1-blocking antibody nivolumab reversed this effect (Fig. 2c). Altogether, these findings indicate that the anti-PD-1 antibody nivolumab can prevent the interaction of

PD-L1 with both membrane-bound and soluble forms of PD-1, and thus inhibit PD-L1-mediated signaling in HL cells that promotes the metabolic activity of tumor cells. DISCUSSION Immune

checkpoint blockade has shown significant clinical efficacy in the treatment of several cancers, including non-small-cell lung cancer21, ovarian cancer22, metastatic melanoma23, and

hematologic malignancies1. In Hodgkin lymphoma, treatment with PD-1 inhibitors has been associated with high objective response rates in the patients with refractory or relapsed

disease11,12,13. Amplification of chromosome 9p24.19 and activation of AP-110 by HRS cells result in increased expression of PD-L1 and/or PD-L2, and interaction of these ligands with PD-1 + 

effector T cells inhibits an effective anti-tumor immune response. Therefore, the underlying mechanism of therapeutic response to PD-1 blockade in Hodgkin lymphoma could be explained by the

fact that the disruption of PD-1/PD-L1 or PD-L2 interaction initiates a cascade of signaling events that reverses the exhausted phenotype in T cells and triggers an effective immune cell

response against tumor cells24. In fact, a recent study indicated that the total number of T cells, as well as the CD4 and CD8 populations, are increased in the peripheral blood of HL

patients who are treated with a PD-1-blocking antibody, supporting the notion that the T-cell-mediated response12 could be a major mechanism accounting for the efficacy of anti-PD-1

antibodies. However, the loss or reduced expression of MHC class I and II molecules on HRS cells14 would be expected to limit neoantigen presentation and subsequent effector T-cell function,

suggesting that additional and/or alternate mechanisms may contribute to the response to PD-1 blockade therapy in HL. A recent report has shown that TAMs constitute the majority of PD-L1 + 

cells within the tumor microenvironment in HL. These cells are in close vicinity of PD-L1 + HRS cells and engage a large number of the PD-1 + T cells, thereby generating an immunosuppressive

niche in cHL8. The PD-1 + T cells predominantly exhibit a CD4 + Th1-polarized T-effector phenotype and are expected to be able to lyse HRS cells when immune checkpoint blockade is used6.

Whether it is TAMs, T cells or a combination of both cell types that promote the anti-tumor immunity following PD-1 blockade has yet to be determined. While T cells and TAMs are shown to be

prevalent in the tumor microenvironment, an increased number of natural killer cells are also found in the peripheral blood circulation, and these cells may be recruited to the tumor and

contribute to the lysis of MHC-deficient malignant cells12. While immune mechanisms may account in part for the efficacy of PD-1 blockade in cHL, we explored whether genetic reasons for PD-1

ligand overexpression provided a growth advantage to HRS cells and whether engagement of the ligands with PD-1 activated the tumor cells directly. Herein, we confirm the presence of reverse

signaling through PD-L1 in the HL cell lines and explored its role in response to anti-PD-1 therapy. We describe that the engagement of PD-L1 using a mouse anti-human agonistic PD-L1

monoclonal antibody (clone B11, in-house generated by Dr. Dong lab) increases the survival of HRS cells by significantly reducing the number apoptotic and dead cells in all four HL cell

lines examined in this study (Fig. 1a). Moreover, the agonistic anti-PD-L1 antibody increases the cell proliferation rate (Fig. 1b) and reduces the protein expression of several apoptotic

proteins (Fig. 1c), indicating that the increased expression of PD-L1 on the cell surface of HL cells promotes proliferation and survival of the tumor cells. In support of these findings,

upregulation of PD-L1 has been shown to promote cell proliferation in pancreatic cancer cells25, a finding we also confirmed by overexpressing PD-L1 using a retroviral system and noting an

increase in the proliferation rate of HL lines (data not shown). Similarly, others have shown that PD-L1 cell-intrinsic signaling protects tumor cells from interferon-induced cytotoxicity

via a non-conventional conserved motif located within the intracellular domain of PD-L1 and leads to tumor progression in both murine and human cell lines26. While this study indicates that

blocking of PD-L1 receptor sensitizes tumor cells to interferon-induced cytotoxicity, no data are available, testing whether PD-1 blockers would induce similar sensitization in HRS cells. In

this report, we show that treatment of HL cells with an agonistic PD-L1 antibody reduces the level of p-P38 and p-ERK (Fig. 1d). In addition, membrane-bound PD-1 also triggered reverse

signaling through PD-L1 (Fig. 2a) and treatment with nivolumab inhibited this effect, suggesting that clinical responses in cHL patients to PD-1-blocking antibodies are, at least in part,

mediated by interrupting PD-L1 signaling. It has previously been reported that the PD-L1 antibodies capable of increasing p-P38 level induce the apoptosis of tumor-infiltrated cytotoxic T

cells16. Therefore, our observation of reduced p-P38 levels, decreased apoptosis, and an increased proliferation rate is consistent with this data and indicates that cell survival and

proliferation and MAPK activity have an inverse correlation in HL cells. However, a previous study has suggested that cross-linking of PD-L1 using a PD-L1 monoclonal antibody (R&D

Systems) induces cell apoptosis in EBV-transformed B cells27, a result that differs from our data that shows reduced apoptosis with an agonistic anti-PD-L1 antibody. The reason for this

discrepancy may be explained by differences in antibody-binding site or cell type. However, the PD-L1 antibody we used (B11 clone) resulted in a similar phenotype as binding to PD-1,

implying that PD-1 and B11 antibody share the same binding site on PD-L1. Future studies are required to address the different binding sites on PD-L1. Our results further showed that the

soluble form of PD-1 is significantly increased in the serum of HL patients when compared with normal subjects (Fig. 2b). The prognostic significance of soluble PD-1 and its ligands has

previously been described in several malignancies, including melanoma, lung, and pancreatic cancers17,18,19,20, but this the first to report that soluble PD-1 is elevated in the circulation

in HL patients. Although the biological properties of soluble PD-1 need to be precisely investigated, data presented in this study found that soluble PD-1 has the ability to induce PD-L1

reverse signaling in HL cell lines, similar to that seen with membrane-bound PD-1. In fact, treatment of the cells with soluble PD-1 increased spare respiratory capacity in three HL cell

lines, and treatment with nivolumab could reverse this effect, suggesting that there is a functional and biological importance to these soluble forms (Fig. 2c). A recent report indicates

that HRS energy metabolism is highly dependent on oxidative phosphorylation due to upregulation of several mitochondrial genes and increased mitochondria biogenesis as compared with germinal

cell B-cells counterparts28. Similarly, another study using immunohistochemical analysis has shown that the markers of mitochondrial oxidative phosphorylation, such as TOMM20 and MCT1, are

higher in HRS cells, but absent in TAM and tumor-associated lymphocytes. Instead, TAMs show increased reactivity for glycolysis marker MCT4 and are dependent on glycolysis, emphasizing the

highly metabolic heterogeneity in cHL. According to this study, the high metabolic heterogeneity is present in the refractory and relapsed cHL (hazard ratio of 5.87)29. Therefore, the

effects of PD-1 blockers on HL patients could be mediated by the disruption of HRS mitochondrial oxidative phosphorylation, and our data suggest that PD-L1 reverse signaling plays a

significant role in this context. In summary, our data identify a role for PD-L1 reverse signaling in promoting tumor cell growth, proliferation, and metabolism in cHL. We also find that

interference with PD-L1 reverse signaling contributes to the therapeutic response seen with anti-PD-1-blocking antibodies in HL patients. METHODS CELLS AND TRANSFECTION HL428, HL1236, HDLM2,

and KMH2 cell lines were obtained from DSMZ (Leibniz-Institut, Germany). Cells were maintained in RPMI-1640 (Gibco), supplemented with 10% FBS (Gibco), 1% penicillin/streptomycin (Corning),

1 mM MEM nonessential amino acids (Corning), and 1× sodium pyruvate (Corning), at 37 °C incubator with 5% CO2. HEK293 cells were cultured in DMEM containing 10% FBS and 1%

penicillin/streptomycin. The basal PD-L1 expression level in all four HL cell lines was determined using flow cytometry (Supplementary Fig. 1A). To determine the role of genetically driven

increased PD-L1 expression, HL cell lines were transfected with PD-L1-coding sequence using the pLEX-MCS Inducible Expression System (Open Biosystems). The gene of interest (GOI) was created

by RT-PCR. Primers were designed to incorporate restrictions sites _XhoI_ (5′) and _AgeI_ (3′) followed by ligation into the pLEX-MCS vector using T4 DNA Ligase (New England Biolabs). DH5a

(_E. coli_) competent cells were used to amplify lentivirus plasmid. The virus was produced according to the manufacturer instructions and introduced into HL cell lines. After 5 days of

exposure to the virus, the transfected cells were selected using puromycin. Fourteen days post transfection, cells were screened for the expression of PD-L1 by flow cytometry (Supplementary

Fig. 1A). MFI for PD-L1 overexpressing HL cells were: HL-428-PD-L1 (Isotype control: 20.4, PD-L1: 1576), HL-1236-PD-L1 (Isotype control: 48, PD-L1: 948), and HL-KMH2-PD-L1 (Isotype control:

35.9, PD-L1: 1496). HEK293 cells were transfected with PD-1-coding sequence using the Retro-X™ Tet-On® 3 G Inducible Expression System (Takara Bio USA, Mountainview, CA). The retrovirus was

produced according to the manufacturer instructions and introduced into HEK293 cell line. After 5 days of exposure to the virus, the cells were selected using puromycin. After 1 week of

selection, the cells were exposed to doxycycline. After 5 days, the cells were screened for expression of PD-1 by FACS, western, and immunohistochemistry. LUMINEX ASSAY Serum samples from 47

Hodgkin lymphoma patients were collected to test the presence of soluble PD1, and 17 normal serum samples were added as a control. The samples were analyzed in a multiplex array using

ProcartaPlex magnetic beads on a Luminex® platform (Austin, Tx). The individual bead, Human PD-1 (CD279) (cat#EPX01A-12214-901), was purchased from ThermoFisher Scientific (Waltham, MA). All

other reagents were supplied by the ProcartaPlex Human Basic Kit (cat#EPX010-10420-901, ThermoFisher Scientific). The bead mix was prepared according to the manufacturer’s protocol. All

serum samples were run in duplicate. Each well in the 96-well plate contained 25 µl of Universal Assay Buffer and 25 µl of patient serum, then analyzed using the Luminex® 200™ instrument.

The data were analyzed using the instrument’s software xPONENT. APOPTOSIS ANALYSIS To determine the effect of PD-L1 ligation on apoptosis, 24-well plates were coated with 10 μg/ml of IgG1

isotype control (Sigma) or an agonistic monoclonal PD-L1 antibody16 (generously provided by Dr. Dong) overnight at 4 °C. HL428 cell lines were starved overnight and incubated on the coated

plates in the starvation medium (RPMI containing 0.5% BSA). Following 48 h, cells were washed with Annexin-V binding buffer (10 mM HEPES, 150 mM NaCl, and 3 mM CaCl2; pH 7.4) and stained

with 5 μl Annexin-V (Fluorescein-conjugate, from Invitrogen) for 30 min and then with 0.5 μg/ml of propidium iodide (PI) (Sigma Aldrich) for 5 min. A minimum of 10,000 cells stained with

Annexin/PI were analyzed using on a BECTON DICKINSON (BD) FACSCANTO II and data were processed by FlowJo software (V10.4). Relative levels of apoptotic-related proteins were determined using

Human Apoptosis Array Kit (R&D Systems), according to the manufacturer’s instructions. Briefly, HL428 cells were starved overnight and then incubated over IgG1 isotype control (Sigma)

or PD-L1 antibody-coated plate for 24 h. Cells were then washed in PBS and lysed with cell lysis buffer supplemented with complete protease inhibitor cocktail (Roche) and halt phosphatase

inhibitor cocktail (Thermo Scientific). In total, 300 μg of total proteins were incubated with the nitrocellulose membranes containing 35 different capture antibodies printed in duplicates,

overnight at 4 °C. The membranes were then washed and incubated with detection antibody cocktail for 1 h at room temperature. The blots were incubated with streptavidin–HRP and Chemi

reagents, respectively, and exposed to X-ray film to detect the protein signals. After scanning the developed X-ray films, the pixel densities were determined using ImageJ analysis software.

OXYGEN CONSUMPTION RATE (OCR) MEASUREMENT To assess the effect of PD-L1 blockade on mitochondrial respiration of the cells, parent line and PD-L1 overexpressing HL cells were starved

overnight and then incubated with the growth medium containing 10 μg/ml recombinant human PD-1 protein (Active Fc Chimera from Abcam) in the presence or absence of 10 μg/ml anti-PD-1

(nivolumab, Bristol-Myers Squibb). Following 3 days, cells were analyzed for OCR using Cell Mito Stress kit (Agilent) and the Seahorse XFe96 Extracellular Flux Analyzer (Seahorse

Bioscience). The optimal cell density and Carbonyl cyanide-4 phenylhydrazone (FCCP) concentration were determined using XF Cell Energy Phenotype Test kit. Briefly, HL cells were resuspended

in Agilent Seahorse XF Base Medium RPMI without phenol red, plated onto Seahorse cells plates (3 × 104–5 × 104) and incubated in CO2-free humidified 37 °C incubator for 1 h. Mitochondrial

respiration function was measured at basal level, which represents the energetic need of a cell under baseline condition. In addition, spare respiratory capacity, an indicative of maximum

capacity or flexibility of a cell to respond to an energetic demand, was assessed by sequential injection of electron transport chain modulators, including 1 μM oligomycin, 1 μM carbonyl

cyanide-4 phenylhydrazone (FCCP), and 1 μM rotenone/antimycin A, over an 80-min period. The analyzed stress test parameters were exported from the analyzer, and the graphs were prepared by

GraphPad Prism (V6) software. FLOW CYTOMETRY Starved HL cells were seeded over isotype control or PD-L1 antibody-coated plates as described above. Forty-eight hours later, cells were in 4%

formaldehyde for 10 min at 37 °C and then permeabilized in ice-cold methanol for 30 min on ice. Cells were then washed and incubated with rabbit mAb to phospho-p38 MAPK (Thr180/Tyr182)

(Clone D3F9, Cell Signaling), rabbit mAB to phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E, Cell Signaling) or Isotype control IgG for 1 h at room temperature, followed with

incubation with secondary Alexa Fluor® 488 AffiniPure F(ab’)2 fragment goat anti-rabbit IgG (H + L) (Jackson Immunoresearch Laboratories) for 30 min at room temperature. The intracellular

levels of phospho-p38 and p-ERK MAPKs were analyzed using FACSCANTO II. CELL PROLIFERATION Proliferating viable cells were determined using CellTiter 96® AQueous One Solution Cell

Proliferation Assay kit (Promega; cat#3580). Ninety-six well plates were first coated using isotype control or PD-L1 antibody as described in previous sections. Starved HL cell lines were

seeded on the coated plated and incubated for additional 48 h. In total, 20 µl of CellTiter 96® AQueous One Solution Reagent was then added to each well of the 96-well assay plate containing

100 µl of cell suspension in the culture medium. Cells were placed at 37 °C cell culture incubator for 2 h before the absorbance was measured at 490 nm using ELISA plate reader (spectraMax

190). WESTERN BLOTTING Dox-induced PD-1 expressing HEK293 cells were cultured in the DMEM containing 10% FBS. Cells were either treated with 2 μg/ml Dox to express PD-1 or left untreated to

serve as the control without PD-1 expression. Dox-induced PD-1 expression by HEK293 cells was confirmed by flow cytometry. HL-428 and HL-1236 cells expressing the green fluorescent protein

(GFP) were starved and then cocultured with control or PD-1 expressing HEK293 cells, in the presence or absence of 10 μg/ml Nivolumab, for 24 h. GFP + cells were then collected by cell

sorting and then lysed and used for western blot analysis using p-ERK, total ERK, and actin antibodies (Cell Signaling). STATISTICAL ANALYSIS Wilcoxon-paired non-parametric test was used to

examine the significant differences between mean values of patients and normal serum samples. All analyses were performed on the GraphPad Prism (V6) software, and data were reported as mean 

± SE. REFERENCES * Ok, C. Y. & Young, K. H. Checkpoint inhibitors in hematological malignancies. _J. Hematol. Oncol._ 10, 103 (2017). Article  Google Scholar  * Goodman, A., Patel, S. P.

& Kurzrock, R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. _Nat. Rev. Clin. Oncol._ 14, 203–220 (2017). Article  CAS  Google Scholar  * Zak, K. M. et al. Structural

biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. _Structure_ 25, 1163–1174 (2017). Article  CAS  Google Scholar  * Portis, T., Dyck, P. & Longnecker, R.

Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. _Blood_ 102, 4166–4178 (2003). Article  CAS 

Google Scholar  * Vockerodt, M. et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin’s Reed-Sternberg-like phenotype.

_J. Pathol._ 216, 83–92 (2008). Article  CAS  Google Scholar  * Cader, F. Z. et al. Mass cytometry of Hodgkin lymphoma reveals a CD4(+) exhausted T-effector and T-regulatory cell rich

microenvironment. _Blood_ 132, 825–836 (2018). CAS  PubMed  Google Scholar  * Greaves, P. et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.

_Blood_ 122, 2856–2863 (2013). Article  CAS  Google Scholar  * Carey, C. D. et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in

Hodgkin lymphoma. _Blood_ 130, 2420–2430 (2017). Article  CAS  Google Scholar  * Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand

expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. _Blood_ 116, 3268–3277 (2010). Article  CAS  Google Scholar 

* Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

_Cancer Res._ 18, 1611–1618 (2012). CAS  Google Scholar  * Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. _N. Engl. J. Med._ 372, 311–319

(2015). Article  Google Scholar  * Armand, P. et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. _J. Clin.

Oncol._ 34, 3733–3739 (2016). Article  CAS  Google Scholar  * Younes, A. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and

brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. _Lancet Oncol._ 17, 1283–1294 (2016). Article  CAS  Google Scholar  * Roemer, M. G. et al. Classical Hodgkin

lymphoma with reduced beta2M/MHC class i expression is associated with inferior outcome independent of 9p24.1 status. _Cancer Immunol. Res._ 4, 910–916 (2016). Article  CAS  Google Scholar 

* Roemer, M. G. M. et al. Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma.

_J. Clin. Oncol._ 36, 942–950 (2018). Article  CAS  Google Scholar  * Liu, X. et al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of

tumor-reactive CD8(+) T cells. _Sci. Rep._ 6, 36722 (2016). Article  CAS  Google Scholar  * Takeuchi, M. et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with

non-small cell lung cancer. _Immunol. Lett._ 196, 155–160 (2018). Article  CAS  Google Scholar  * Okuma, Y. et al. High plasma levels of soluble programmed cell death ligand 1 are

prognostic for reduced survival in advanced lung cancer. _Lung Cancer_ 104, 1–6 (2017). Article  Google Scholar  * Kruger, S. et al. Serum levels of soluble programmed death protein 1

(sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. _Oncoimmunology_ 6, e1310358 (2017). Article  Google Scholar  * Zhou, J. et al. Soluble PD-L1 as a

Biomarker in malignant melanoma treated with checkpoint blockade. _Cancer Immunol. Res._ 5, 480–492 (2017). Article  CAS  Google Scholar  * Xia, B. & Herbst, R. S. Immune checkpoint

therapy for non-small-cell lung cancer: an update. _Immunotherapy_ 8, 279–298 (2016). Article  CAS  Google Scholar  * Zhu, X. & Lang, J. Programmed death-1 pathway blockade produces a

synergistic antitumor effect: combined application in ovarian cancer. _J. Gynecol. Oncol._ 28, e64 (2017). Article  Google Scholar  * Jacquelot, N. et al. Predictors of responses to immune

checkpoint blockade in advanced melanoma. _Nat. Commun._ 8, 592 (2017). Article  CAS  Google Scholar  * Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in

tolerance and immunity. _Annu. Rev. Immunol._ 26, 677–704 (2008). Article  CAS  Google Scholar  * Song, X., Liu, J., Lu, Y., Jin, H. & Huang, D. Overexpression of B7-H1 correlates with

malignant cell proliferation in pancreatic cancer. _Oncol. Rep._ 31, 1191–1198 (2014). Article  CAS  Google Scholar  * Gato-Canas, M. et al. PDL1 Signals through conserved sequence motifs to

overcome interferon-mediated cytotoxicity. _Cell Rep._ 20, 1818–1829 (2017). Article  CAS  Google Scholar  * Kim, Y. S. et al. Cross-linking of B7-H1 on EBV-transformed B cells induces

apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. _J. Immunol._ 181, 6158–6169 (2008). Article  CAS  Google Scholar  * Birkenmeier, K. et

al. Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation. _Int. J. Cancer_ 138, 2231–2246 (2016). Article  CAS  Google Scholar  *

Mikkilineni, L. et al. Hodgkin lymphoma: a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. _Semin. Oncol._ 44, 218–225 (2017). Article  CAS  Google

Scholar  Download references ACKNOWLEDGEMENTS The authors acknowledge specialized programs of research excellence (SPORE) in lymphoma for supporting this study (P50 CA97274) and Mayo Clinic

tumor biobank and Predolin Foundation for providing HL patients serum samples. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Division of Hematology and Internal Medicine, Mayo Clinic,

Rochester, MN, USA Shahrzad Jalali, Tammy Price-Troska, Cole Bothun, Jose Villasboas, Hyo-Jin Kim, Zhi-Zhang Yang, Anne J. Novak & Stephen M. Ansell * Department of Immunology, College

of Medicine, Mayo Clinic, Rochester, MN, USA Haidong Dong Authors * Shahrzad Jalali View author publications You can also search for this author inPubMed Google Scholar * Tammy Price-Troska

View author publications You can also search for this author inPubMed Google Scholar * Cole Bothun View author publications You can also search for this author inPubMed Google Scholar * Jose

Villasboas View author publications You can also search for this author inPubMed Google Scholar * Hyo-Jin Kim View author publications You can also search for this author inPubMed Google

Scholar * Zhi-Zhang Yang View author publications You can also search for this author inPubMed Google Scholar * Anne J. Novak View author publications You can also search for this author

inPubMed Google Scholar * Haidong Dong View author publications You can also search for this author inPubMed Google Scholar * Stephen M. Ansell View author publications You can also search

for this author inPubMed Google Scholar CONTRIBUTIONS S.J. designed the experiments, performed the experiments, and wrote the paper. T.P.-T. and H.-J.K. helped in performing some

experiments. J.V., Z.-Z.Y., and A.J.N. provided scientific inputs. H.D. provided scientific advice. S.M.A. supervised the whole study and provided scientific input. CORRESPONDING AUTHORS

Correspondence to Shahrzad Jalali or Stephen M. Ansell. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare that they have no conflict of interest. ADDITIONAL INFORMATION

PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURE

LEGEND. SUPPLEMENTARY FIG.1. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons

license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a

credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted

use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Jalali, S., Price-Troska, T., Bothun, C. _et al._ Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. _Blood

Cancer Journal_ 9, 22 (2019). https://doi.org/10.1038/s41408-019-0185-9 Download citation * Received: 14 August 2018 * Revised: 11 December 2018 * Accepted: 21 December 2018 * Published: 19

February 2019 * DOI: https://doi.org/10.1038/s41408-019-0185-9 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative